The cancer antibody drug conjugate developer secured the return of Boehringer Ingelheim Venture Fund ahead of early clinical trials on its lead candidate.
Pharmaceutical firm Boehringer Ingelheim’s Venture Fund (BIVF) and diversified holding company PPF Group yesterday co-led a $22m series C round for Switzerland-based cancer antibody developer NBE Therapeutics.
NBE’s existing private shareholders all participated, however none were identified in the press release.
Founded in 2012, NBE Therapeutics is working on cancer treatments which combine antibody drug conjugates with an existing chemotherapy called anthracycline to stimulate the immune system and kill off cancerous cells.
The funding will sustain early clinical development from…